医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
一般論文
In vitro 実験系によるFOLFIRI 療法およびmFOLFOX 6 療法レジメンの有効性およびEGFR 発現変動の評価
林 えり子小林 正紀高橋 夏子平野 剛板垣 史郎山田 武宏井関 健
著者情報
ジャーナル フリー

2010 年 36 巻 12 号 p. 855-862

詳細
抄録

Recently,the number of patients with colorectal cancer has been increasing.Many patients are not aware of any symptoms until the disease is advanced.It is important to select effective regimens for colorectal cancer therapy and combination therapy with a molecular-targeted agent has recently been used for this purpose.However,the effects of anticancer drugs on epidermal growth factor receptor (EGFR),a molecular-targeted protein,have not been clarified.We therefore evaluated the effects of folinic acid/5-fluorouracil/irinotecan (FOLFIRI) and folinic acid/5-fluorouracil/oxaliplatin (mFOLFOX citation=6)treatments,using the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT) assay,as well as the effects of these treatments on EGFR expression in LoVo cells.
The results suggested that 5-fluorouracil and irinotecan have a stronger antiproliferative effect than oxaliplatin.The reduction in viability for LoVo cells treated with FOLFIRI was greater than that for Lovo cells treated with mFOLFOX 6 on day 22.Moreover,EGFR mRNA and protein levels were increased more by mFOLFOX 6 than by FOLFIRI.These results suggest that FOLFIRI therapy may be more effective than mFOLFOX 6 therapy against LoVo cells in consideration of EGFR expression.

著者関連情報
© 2010 日本医療薬学会
前の記事 次の記事
feedback
Top